Gamaleya Research Institute 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678910111213...3233»
  • ||||||||||  Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    A study on cutaneous adverse events of Covid Vaccine () -  Jul 3, 2023 - Abstract #WCD2023WCD_3902;    
    Study included 52 subjects (Females 55%), 59.6% in 30-40 years age group, 93% had taken Covishield, 5% Covaxin and 2% Sputnik V. Time of onset of lesions after vaccination: In 55.7% within 7 days, 36.6% between 7 to 15 days and 7.7% between 15-30 days... The varied cutaneous adverse events post covid vaccination observed in our study and many similar studies published, makes it important to consider the possibility of covid vaccine related inflammatory and autoimmune phenomena.
  • ||||||||||  Ocrevus (ocrelizumab) / Roche, Biogen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Serological response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina. (Pubmed Central) -  Jul 2, 2023   
    The varied cutaneous adverse events post covid vaccination observed in our study and many similar studies published, makes it important to consider the possibility of covid vaccine related inflammatory and autoimmune phenomena. We found that MS patients that received Sputnik V or AstraZeneca vaccines for SARS-CoV-2 developed a serological response with no differences between the vaccines used.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Catalase Activity of IgGs of Patients Infected with SARS-CoV-2. (Pubmed Central) -  Jul 2, 2023   
    We here show that the IgGs from patients who recovered from COVID-19 had the highest catalase activity, and this was statistically significantly higher each compared to the healthy donors (1.9-fold), healthy volunteers vaccinated with Sputnik V (1.4-fold), and patients vaccinated after recovering from COVID-19 (2.1-fold). These data indicate that COVID-19 infection may stimulate the production of antibodies that degrade hydrogen peroxide, which is harmful at elevated concentrations.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal, PD(L)-1 Biomarker, IO biomarker:  Phenotypic Changes in T and NK Cells Induced by Sputnik V Vaccination. (Pubmed Central) -  Jun 28, 2023   
    A short-term elevation of the activating NKG2D and CD16 was observed in NK cells. Overall, the findings of the study are in favor of the Sputnik V vaccine not provoking a dramatic phenotypic rearrangement in T and NK cells, although it induces their slight temporal non-specific activation.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Reactive Arthritis after Gam-COVID-Vac Vaccination: A Case Report. (Pubmed Central) -  Jun 21, 2023   
    Although the safety and efficacy of vaccinations have been evaluated through clinical trials, medical experts and authorities are very interested in the reporting and investigation of adverse events following SARS-CoV-2 immunization in the general public. This article reports a 41-year-old man without history of underlying diseases, complaining of continuous morning stiffness and acute discomfort in his left elbow joint, 20 days after taking the first dosage of Sputnik V. The case was extensively studied, and a possible diagnosis of reactive arthritis was made.
  • ||||||||||  Journal:  Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities. (Pubmed Central) -  Jun 16, 2023   
    Various natural compounds such as sarsapogenin, lycorine, biscoclaurine, vitamin B, glycyrrhizic acid, riboflavin, resveratrol and kaempferol, various vaccines and drugs such as AZD1222, mRNA-1273, BNT162b2, Sputnik V, and remdesivir, lopinavir, favipiravir, darunavir, oseltamivir, and umifenovir, resp., have been discussed comprehensively. We attempted to provide exhaustive information regarding the various prospective therapeutic approaches available in order to assist researchers and physicians in treating COVID-19 patients.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  Antibody responses to mRNA versus non-mRNA COVID vaccines among the Mongolian population. (Pubmed Central) -  Jun 13, 2023   
    The BNT162b2 vaccine showed the highest level of antibody against SARS-CoV-2, followed by the BBIBP-CorV, Gam-COVID-Vac, and ChAdOx1 n-CoV-19 vaccines. The level of antibodies was increased in people infected with SARS-CoV-2 after vaccination, as compared to uninfected but vaccinated individuals.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    EVALUATION OF ANTIBODY RESPONSES TO SARS-COV-2 VACCINES IN PATIENTS WITH CKD (ePoster (Virtual Only)) -  Jun 9, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2301;    
    Increasing age, history of CVD and lower eGFR were factors associated with a non-response. Potential differences between COVID-19 vaccines should be explored in prospective long-term follow-up studies.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal, Real-world evidence, Real-world effectiveness, Real-world:  Real-World Effectiveness of Four Types of COVID-19 Vaccines. (Pubmed Central) -  May 27, 2023   
    All four vaccines evaluated in this study showed effectiveness against asymptomatic COVID-19 infection, symptomatic infection, hospitalization, and death. Furthermore, BNT162b2, BBIBP-CorV, and ChAdOx1 nCoV-19 induced high levels of immunology markers within one month of vaccination.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    FREQUENCY OF VACCINE-RELATED ADVERSE EVENTS IN PATIENTS WITH RHEUMATIC DISEASE () -  May 19, 2023 - Abstract #EULAR2023EULAR_3322;    
    The adverse events according to the type of COVID-19 vaccine were the following: Sputnik-V 80%, Pfizer 76.6% and AstraZeneca 76.1%, without statistically significant difference between vaccine types...Providing this information to patients is important to improve vaccine acceptance. In addition, the administration of NSAID after the application of the vaccine could be proposed to reduce the presence of side effects.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Vaccination situation against COVID-19 in an adults cystic fibrosis center in Argentina (Poster Area) -  May 9, 2023 - Abstract #ECFS2023ECFS_659;    
    There were no episodes of severe COVID-19 after administration of tixagevimab/cilgavimab. Given the need to complete the vaccination, heterologous schemes were used and although the COVID-19 pandemic is entering a control phase, boosters must be insisted on to maintain immunity in this population.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal, Adverse events:  Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers in Shoushtar, Iran. (Pubmed Central) -  May 8, 2023   
    The majority of participants did not show life-threatening side effects after the injection of 1 of the 4 studied vaccines. Since it was well accepted and tolerable by the participants, it can be used widely and safely against SARS-CoV-2.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    THE NUTRITIONAL ASSESSMENT TOOLS TO IDENTIFY PATIENTS AT INCREASED SARCOPENIA RISK (Focussed Oral Room 7) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1670;    
    The NRI-JH and GNRI were significantly associated with risk of sarcopenia. The NRI-JH demonstrated a stronger association with the risk of sarcopenia compared to the GNRI.
  • ||||||||||  Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Review, Journal:  Tracking the COVID-19 vaccines: The global landscape. (Pubmed Central) -  Apr 14, 2023   
    Thus, the present report provides data that will contribute to decisions making about the vaccine implementation plans of action for, not only our region but our country to support the fight against the COVID-19 global pandemic. COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; VLPs: Virus like particles; WHO: World Health Organization; E: Envelope; M: Membrane; S: Spike; N: Nucleocapsid; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; FDA: Food and Drug Administration; LNP: lipid-nanoparticle; AZD1222: ChAdOx1 nCoV-19; BNT162b2: Pfizer-BioNTech mRNA vaccine; mRNA-1273: Moderna vaccine; Ad26.COV2.S: Johnson and Johnson - Janssen's vaccine; Gam-COVID-Vac: Sputnik Vaccine; NVX-CoV2373: Novavax vaccine with Matrix-M
  • ||||||||||  Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal, Adverse events:  Side effects of Sputnik V, Oxford-AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran. (Pubmed Central) -  Apr 4, 2023   
    COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; VLPs: Virus like particles; WHO: World Health Organization; E: Envelope; M: Membrane; S: Spike; N: Nucleocapsid; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; FDA: Food and Drug Administration; LNP: lipid-nanoparticle; AZD1222: ChAdOx1 nCoV-19; BNT162b2: Pfizer-BioNTech mRNA vaccine; mRNA-1273: Moderna vaccine; Ad26.COV2.S: Johnson and Johnson - Janssen's vaccine; Gam-COVID-Vac: Sputnik Vaccine; NVX-CoV2373: Novavax vaccine with Matrix-M Compared to Sinopharm or Covaxin, the Sputnik V and Oxford-AstraZeneca vaccines were associated with a higher prevalence of SEs, a greater number of SEs per individual, and more severe SEs.
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    KIDNEY TRANSPLANTATION DURING THE THREE YEARS (2020-2022) OF COVID-19 PANDEMIC: SINGLE-CENTER EXPERIENCE () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1623;    
    Since 2022 we started to use remdesivir in recipients with symptomatic course of disease with positive results...There were no revealed any adverse effects of vaccination among our group. Conclusions In our experience, the current kidney transplant program seems viable and safe, even during periods of health emergencies.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    A COMPARISON OF GAM-COVID-VAC (SPUTNIK V) VACCINE IMMUNOGENICITY IN HEMODIALYSIS PATIENTS AND NON-RENAL SUBJECTS () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1616;    
    Introduction We report results on immunogenicity of the recombinant adenovirus (rAd) 26 and rAd5 vector-based COVID-19 vaccine Gam-COVID-Vac (Sputnik V, developed by Gamaleya National Research Centre, Russia) in patients, receiving maintenance hemodialysis (HD)...Cellular response turned up to be more sustained over time in HD group. View Large Image Figure Viewer Download Hi-res image Download (PPT)
  • ||||||||||  Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Trial completion date:  FH-63: Phase IIB Study of Recombinant Novel Coronavirus Vaccine (clinicaltrials.gov) -  Mar 14, 2023   
    P2b,  N=450, Active, not recruiting, 
    The adverse effects of AZD1222 were greater than those of other vaccines. Trial completion date: Jan 2023 --> Apr 2023
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Neurological Manifestations Post-COVID-19 Vaccination: A Review of Case Studies (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_3864;    
    Design/Methods A thorough literature search of Google Scholar and PubMed was conducted from December 2020 to October 2021, which included case reports of neurological complications with the following COVID-19 vaccines: Pfizer-BioNTech, Moderna, J&J/Janssen, AstraZeneca, Sinovac-CoronaVac, Sputnik V, and COVAXIN...Conclusions Several post-marketing CNS and PNS adverse events have occurred following the COVID-19 vaccination, including CVST, GBS, and TM. Further studies with non-vaccinated controls might help understand the pathophysiologic mechanisms of these neurological manifestations.
  • ||||||||||  Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
    Enrollment change, Trial primary completion date:  CovicompareG: Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea (clinicaltrials.gov) -  Feb 16, 2023   
    P2,  N=200, Recruiting, 
    To enhance Africa's contribution to the global knowledge on COVID-19 vaccine safety, governments must explicitly consider safety monitoring as a priority, and funding organizations need to systematically and continuously support these programs. N=400 --> 200 | Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    Journal:  T-Cell Immunity in COVID-19-Recovered Individuals and Individuals Vaccinated with the Combined Vector Vaccine Gam-COVID-Vac. (Pubmed Central) -  Feb 12, 2023   
    release by single sensitized T-cells in response to specific stimulation in recovered and vaccinated individuals did not result in the accumulation of this and other cytokines in the culture medium. These findings suggest a balance between cytokine production and utilization by immunocompetent cells as a prerequisite for providing a controlled cytokine signal and avoiding a "cytokine storm".